- Home
- INTA vs AUPH Comparison
INTA vs AUPH Comparison
Compare INTA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTA | AUPH |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INTA | AUPH |
|---|---|---|
| Price | $22.00 | $16.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $41.43 | $17.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.89 | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $504,120,000.00 | $283,055,000.00 |
| Revenue This Year | $15.91 | $17.54 |
| Revenue Next Year | $13.78 | $15.74 |
| P/E Ratio | ★ N/A | $65.84 |
| Revenue Growth | 17.09 | ★ 20.38 |
| 52 Week Low | $19.01 | $7.29 |
| 52 Week High | $53.81 | $16.88 |
Technical Indicators
Market Signals| Indicator | INTA | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 60.55 |
| Support Level | $20.04 | $14.60 |
| Resistance Level | $25.83 | $16.88 |
| Average True Range (ATR) | 1.44 | 0.52 |
| MACD | -0.15 | 0.07 |
| Stochastic Oscillator | 13.75 | 86.17 |
Price Performance
Historical ComparisonAbout INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.